The control arm of the phase III VIVIANE (Human PapillomaVIrus: Vaccine Immunogenicity
ANd Efficacy; NCT00294047) study in women> 25 years was studied to assess risk of …

Background: We describe transition probabilities for incident human papillomavirus (HPV)
16/18/31/33/35/45/52/58/59 infections and cervical intraepithelial neoplasia (CIN) 1 lesions …

Little is known about the dynamics of human papillomavirus (HPV) infection and subsequent
development of high-grade cervical intraepithelial neoplasia (CIN2/3), particularly in …

Health professionals and the public need to understand the natural history of human
papillomavirus (HPV) infections of the cervix to best use the information provided by new …

Infection with high‐risk human papillomavirus (HR‐HPV) is transient and clears on its own in
majority of the women. Only a few women who have persistent infection may finally develop …

Background: We analyzed data from a cohort of 553 women enrolled in the placebo arm of a
randomized controlled trial of the human papillomavirus (HPV) 16/18 vaccine to study the …

Background: Human papillomavirus (HPV) types 16 and 18 cause 60%–70% of cervical
cancer worldwide, and other HPV types cause virtually all remaining cases. Pooled HPV …

Background The control arm of PATRICIA (PApillomaTRIal against Cancer In young Adults,
NCT00122681) was used to investigate the risk of progression from cervical HPV infection to …

Background Infection with high-risk human papillomavirus (HPV) is the main cause of high-
grade cervical intraepithelial neoplasia (CIN) and cancer. It has been suggested that …

Background Human papillomavirus (HPV) persistence is the pivotal event in cervical
carcinogenesis. We followed a large-scale community-based cohort for 16 years to …